Shanghai Gracell Biotechnologies

Gracell Biotechnologies is a clinical-stage biopharmaceutical company focused on developing transformative cell therapies for cancer and autoimmune diseases. The company utilizes its proprietary FasTCAR and TruUCAR platforms to address key limitations in CAR-T therapy, such as lengthy manufacturing cycles and the need for patient-specific starting materials. Its lead candidate, GC012F, is a dual-targeting autologous CAR-T therapy currently being evaluated for multiple myeloma and systemic lupus erythematosus. In early 2024, Gracell was acquired by AstraZeneca for approximately $1.2 billion, integrating its innovative pipeline and manufacturing capabilities into AstraZeneca's global oncology and immunology portfolio.